This is a first-in-human study to evaluate the safety, tolerability, and pharmacodynamics of a single IV infusion of NBIB-223 in participants with Friedreich’s Ataxia.
There are 3 participant groups/arms planned:
- Part A: Dose escalation in adults
- Part B: Dose expansion in pediatrics
- Part C: Dose expansion in adult and/or pediatric participants with FA-related cardiomyopathy
Anyone considering participating in a clinical trial should discuss the matter with their physician. FARA does not endorse or recommend any particular studies.
Study Details:
Key Inclusion Criteria:
- Clinical and genetic diagnosis of Friedreich’s Ataxia.
- Diagnosed before age 16.
- GAA repeat expansion in both alleles.
- Resides in the United States.
- mFARS overall score ≥15 and <80, and an Upright Stability (mFARS-E) gait score of ≥1.
- Omaveloxolone use:
- If currently taking omaveloxolone, must have started at least 1 year ago and have been on a stable dose for at least 12 weeks with no anticipated dose adjustments during the 48-week period following NBIB-223 infusion.
- If not currently taking omaveloxolone, must agree not to start during the 48-week period following NBIB-223 infusion.
Key Exclusion Criteria:
- Pregnant, plan to become pregnant during the first 12 months of the study, or lactating.
- Previous exposure to adeno-associated virus (AAV)-9 as determined by the presence of anti-AAV9 antibodies.
- Contraindication to cerebrospinal fluid collection via lumbar puncture, magnetic resonance imaging with contrast, or endomyocardial biopsy.
- Clinically significant cardiac valve disease, obstructive cardiac disease, or arrhythmias.
- Uncontrolled diabetes (hemoglobin [Hb] A1c >8.0%).
- Planned surgery for scoliosis, foot deformity, or other indications during the first 18 months.
- Previously treated with cellular or gene therapy.
- Participated in any other interventional clinical study within 30 days.
Additional inclusion/exclusion criteria may apply, per protocol.